Legal & General Group Plc Raises Holdings in Healthpeak Properties, Inc. $DOC

Legal & General Group Plc grew its stake in Healthpeak Properties, Inc. (NYSE:DOC) by 9.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,051,114 shares of the real estate investment trust’s stock after purchasing an additional 580,870 shares during the period. Legal & General Group Plc’s holdings in Healthpeak Properties were worth $113,382,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of DOC. Integrated Wealth Concepts LLC boosted its position in Healthpeak Properties by 7.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 18,084 shares of the real estate investment trust’s stock worth $366,000 after purchasing an additional 1,231 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Healthpeak Properties by 110.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 121,881 shares of the real estate investment trust’s stock worth $2,463,000 after purchasing an additional 63,930 shares in the last quarter. Woodline Partners LP boosted its position in Healthpeak Properties by 41.3% in the 1st quarter. Woodline Partners LP now owns 59,103 shares of the real estate investment trust’s stock worth $1,195,000 after purchasing an additional 17,279 shares in the last quarter. Brown Advisory Inc. boosted its position in Healthpeak Properties by 3.1% in the 2nd quarter. Brown Advisory Inc. now owns 46,770 shares of the real estate investment trust’s stock worth $819,000 after purchasing an additional 1,415 shares in the last quarter. Finally, Qube Research & Technologies Ltd purchased a new stake in Healthpeak Properties in the 2nd quarter worth approximately $3,117,000. Hedge funds and other institutional investors own 93.57% of the company’s stock.

Insider Activity at Healthpeak Properties

In other Healthpeak Properties news, insider Scott R. Bohn sold 10,989 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $19.45, for a total transaction of $213,736.05. Following the completion of the transaction, the insider owned 7,636 shares of the company’s stock, valued at $148,520.20. This represents a 59.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.23% of the stock is owned by insiders.

Healthpeak Properties Stock Performance

Shares of DOC stock opened at $19.49 on Friday. The company has a market capitalization of $13.44 billion, a P/E ratio of 60.90, a P/E/G ratio of 2.52 and a beta of 1.00. The business’s 50 day moving average is $17.70 and its two-hundred day moving average is $17.32. The company has a current ratio of 2.96, a quick ratio of 2.96 and a debt-to-equity ratio of 1.15. Healthpeak Properties, Inc. has a 12-month low of $15.70 and a 12-month high of $20.27.

Healthpeak Properties (NYSE:DOC) last issued its quarterly earnings results on Tuesday, May 5th. The real estate investment trust reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.02. The company had revenue of $752.95 million for the quarter, compared to the consensus estimate of $694.59 million. Healthpeak Properties had a return on equity of 2.61% and a net margin of 7.73%.Healthpeak Properties’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.46 earnings per share. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. Analysts expect that Healthpeak Properties, Inc. will post 1.75 EPS for the current fiscal year.

Healthpeak Properties Dividend Announcement

The company also recently announced a monthly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 15th will be issued a dividend of $0.1017 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a c) dividend on an annualized basis and a dividend yield of 6.3%. Healthpeak Properties’s dividend payout ratio is presently 381.25%.

Wall Street Analyst Weigh In

DOC has been the topic of several recent research reports. Royal Bank Of Canada upped their price objective on Healthpeak Properties from $20.00 to $21.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. Scotiabank upped their price objective on Healthpeak Properties from $19.00 to $21.00 and gave the stock a “sector perform” rating in a research report on Wednesday. Citigroup increased their price target on Healthpeak Properties from $17.50 to $20.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. Robert W. Baird increased their price target on Healthpeak Properties from $19.00 to $21.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 13th. Finally, Morgan Stanley increased their price target on Healthpeak Properties from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, May 22nd. Five investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $19.23.

Healthpeak Properties Profile

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.